105 related articles for article (PubMed ID: 23431113)
1. Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.
Dingemanse J; Hoever P; Hoch M; Treiber A; Wagner-Redeker W; Miraval T; Hopfgartner G; Shakeri-Nejad K
Drug Metab Dispos; 2013 May; 41(5):1046-59. PubMed ID: 23431113
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
5. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
6. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.
Hoever P; de Haas S; Winkler J; Schoemaker RC; Chiossi E; van Gerven J; Dingemanse J
Clin Pharmacol Ther; 2010 May; 87(5):593-600. PubMed ID: 20376002
[TBL] [Abstract][Full Text] [Related]
7. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C
Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073
[TBL] [Abstract][Full Text] [Related]
8. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.
Hoch M; Hoever P; Zisowsky J; Priestley A; Fleet D; Dingemanse J
Pharmacology; 2012; 89(1-2):53-7. PubMed ID: 22302127
[TBL] [Abstract][Full Text] [Related]
9. Orexin receptor antagonism: an ascending multiple-dose study with almorexant.
Hoever P; de Haas SL; Dorffner G; Chiossi E; van Gerven JM; Dingemanse J
J Psychopharmacol; 2012 Aug; 26(8):1071-80. PubMed ID: 22695489
[TBL] [Abstract][Full Text] [Related]
10. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.
Steiner MA; Lecourt H; Strasser DS; Brisbare-Roch C; Jenck F
Neuropsychopharmacology; 2011 Mar; 36(4):848-56. PubMed ID: 21150905
[TBL] [Abstract][Full Text] [Related]
12. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
13. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant.
Dietrich H; Jenck F
Psychopharmacology (Berl); 2010 Oct; 212(2):145-54. PubMed ID: 20631993
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
15. The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.
Steiner MA; Lecourt H; Jenck F
Psychopharmacology (Berl); 2012 Oct; 223(4):465-75. PubMed ID: 22592903
[TBL] [Abstract][Full Text] [Related]
16. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration.
Srinivasan S; Simms JA; Nielsen CK; Lieske SP; Bito-Onon JJ; Yi H; Hopf FW; Bonci A; Bartlett SE
PLoS One; 2012; 7(9):e44726. PubMed ID: 23028593
[TBL] [Abstract][Full Text] [Related]
17. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.
Shakeri-Nejad K; Hoch M; Hoever P; Dingemanse J
Eur J Pharm Sci; 2013 Aug; 49(5):836-44. PubMed ID: 23770377
[TBL] [Abstract][Full Text] [Related]
18. Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects.
Hoch M; Hoever P; Haschke M; Krähenbühl S; Dingemanse J
J Clin Pharmacol; 2011 Jul; 51(7):1116-21. PubMed ID: 20852003
[No Abstract] [Full Text] [Related]
19. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
20. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
